NASDAQ:APLS

Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

$38.04

-1.63 (-4.11%)

(As of 09/29/2023 ET)

Compare

Today's Range: $37.93
▼
$40.42
50-Day Range: $23.65
▼
$48.53
52-Week Range: $19.83
▼
$94.75

Volume: 1.86 million shs
Average Volume: 2.66 million shs
Market Capitalization: $4.48 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $66.13

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 73.9% Upside
$66.13 Price Target
Short Interest: Bearish
11.56% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.27
Upright™ Environmental Score
News Sentiment: 0.61
Based on 18 Articles This Week
Insider Trading: Selling Shares
$10.57 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.89) to ($2.77) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

132nd out of 972 stocks

Pharmaceutical Preparations Industry

42nd out of 451 stocks

4.4

Analyst's Opinion

Consensus Rating
Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $66.13, Apellis Pharmaceuticals has a forecasted upside of 73.9% from its current price of $38.04.
Amount of Analyst Coverage
Apellis Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
11.56% of the outstanding shares of Apellis Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Apellis Pharmaceuticals has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Apellis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Apellis Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Apellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Apellis Pharmaceuticals is -1.27.

2.6

News and Social Media Coverage

News Sentiment
Apellis Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for Apellis Pharmaceuticals this week, compared to 6 articles on an average week.
Search Interest
Only 33 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.
MarketBeat Follows
18 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 64% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,568,621.00 in company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Apellis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
90.43% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($4.89) to ($2.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Apellis Pharmaceuticals is -6.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Apellis Pharmaceuticals is -6.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Apellis Pharmaceuticals has a P/B Ratio of 24.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Price History

30 days | 90 days | 365 days | Advanced Chart

APLS Stock News Headlines

September 29, 2023 | tmcnet.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

September 29, 2023 | markets.businessinsider.com

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm

October 1, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 28, 2023 | barrons.com

MONDAY INVESTOR DEADLINE: Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

September 28, 2023 | americanbankingnews.com

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from Analysts

September 27, 2023 | msn.com

Apellis Pharmaceuticals sinks amid new short report

September 27, 2023 | americanbankingnews.com

Apellis Pharmaceuticals (NASDAQ:APLS) Receives Buy Rating from HC Wainwright

September 25, 2023 | stockhouse.com

OCTOBER 2 DEADLINE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

October 1, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

September 25, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and DENTSPLY SIRONA (XRAY)

September 25, 2023 | finance.yahoo.com

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

September 24, 2023 | prnewswire.com

APLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS

September 24, 2023 | americanbankingnews.com

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%

September 22, 2023 | benzinga.com

Apellis Pharmaceuticals Unusual Options Activity For September 22

September 22, 2023 | americanbankingnews.com

Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 20,350 Shares of Stock

September 21, 2023 | markets.businessinsider.com

Robert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS)

September 21, 2023 | americanbankingnews.com

Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Buy" Rating from HC Wainwright

September 20, 2023 | markets.businessinsider.com

Apellis Pharmaceuticals: Strong Competitive Positioning and Safety Confidence Reinforce Buy Rating

September 19, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Boston Scientific (BSX), Apellis Pharmaceuticals (APLS) and Healthequity (HQY)

September 19, 2023 | barrons.com

S&P 500 Futures Climb in Premarket Trading; Apellis Pharmaceuticals, Liberty Media SiriusXM A Lead

September 19, 2023 | proactiveinvestors.com

Apellis Pharmaceuticals gets schadenfreude lift as rival trial fails

September 19, 2023 | proactiveinvestors.com

Apellis Pharmaceuticals sees schadenfreude stock boost as rival trial fails

September 19, 2023 | msn.com

Apellis spikes as Astellas posts long-term data for rival product

September 16, 2023 | markets.businessinsider.com

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

September 15, 2023 | msn.com

Wells Fargo ups Apellis to overweight, stock climbs 8%

September 15, 2023 | msn.com

Wells Fargo Upgrades Apellis Pharmaceuticals (APLS)

September 11, 2023 | benzinga.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline

See More Headlines

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings: 7/31/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APLS
CUSIP: N/A
CIK: 1492422
Web: www.apellis.com
Phone: (617) 977-5700
Fax: N/A
Employees: 767
Year Founded: 2009

Price Target and Rating

Average Stock Price Forecast: $66.13
High Stock Price Forecast: $141.00
Low Stock Price Forecast: $29.00
Forecasted Upside/Downside: +73.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-652,170,000.00
Net Margins: -356.02%
Pretax Margin: -356.37%
Return on Equity: -212.82%
Return on Assets: -74.50%

Debt

Debt-to-Equity Ratio: 0.27
Current Ratio: 5.11
Quick Ratio: 4.52

Sales & Book Value

Annual Sales: $75.42 million
Price / Sales: 59.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.54 per share
Price / Book: 24.70

Miscellaneous

Outstanding Shares: 117,740,000
Free Float: 108,907,000
Market Cap: $4.48 billion
Optionable: Not Optionable
Beta: 1.08

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Cedric Francois M.D. (Age 51)
Ph.D., Co-Founder, Pres, CEO & Director
Comp: $1.2M

Dr. Pascal Deschatelets Ph.D. (Age 53)
Co-Founder & Chief Scientific Officer
Comp: $688.05k

Mr. Alec Machiels J.D. (Age 50)
MBA, Co-Founder & Director
Comp: $72.5k

Mr. Timothy E. Sullivan (Age 52)
CFO & Treasurer
Comp: $716.41k

Mr. David O. Watson Esq. (Age 50)
J.D., Gen. Counsel
Comp: $675.35k

Mr. Adam J. Townsend (Age 46)
Chief Commercial Officer
Comp: $701.61k

Ms. Nur Nicholson (Age 54)
Chief Technical Operations Officer

Mr. James G. Chopas CPA (Age 57)
VP, Corp. Controller & Chief Accounting Officer

Ms. Meredith Kaya
Sr. VP, Investor Relations & Strategic Fin.

Ms. Karen Lewis (Age 51)
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.
What is Apellis Pharmaceuticals' stock price forecast for 2023?: 15 Wall Street analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $29.00 to $141.00. On average, they anticipate the company's share price to reach $66.13 in the next year. This suggests a possible upside of 73.9% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.
How have APLS shares performed in 2023?: Apellis Pharmaceuticals' stock was trading at $51.71 at the start of the year. Since then, APLS shares have decreased by 26.4% and is now trading at $38.04.
View the best growth stocks for 2023 here.
Are investors shorting Apellis Pharmaceuticals?: Apellis Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 13,610,000 shares, an increase of 10.6% from the August 31st total of 12,310,000 shares. Based on an average daily trading volume, of 4,730,000 shares, the short-interest ratio is presently 2.9 days.
View Apellis Pharmaceuticals' Short Interest.
When is Apellis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our APLS earnings forecast.
How were Apellis Pharmaceuticals' earnings last quarter?: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its earnings results on Monday, July, 31st. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.33. The company earned $95 million during the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 212.82% and a negative net margin of 356.02%. The company's revenue was up 482.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.46) EPS.
What ETFs hold Apellis Pharmaceuticals' stock?: ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI).
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?: 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).
When did Apellis Pharmaceuticals IPO?: (APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.
What is Apellis Pharmaceuticals' stock symbol?: Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."
How do I buy shares of Apellis Pharmaceuticals?: Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Apellis Pharmaceuticals' stock price today?: One share of APLS stock can currently be purchased for approximately $38.04.
How much money does Apellis Pharmaceuticals make?: Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $4.48 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.
How many employees does Apellis Pharmaceuticals have?: The company employs 767 workers across the globe.
Does Apellis Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
How can I contact Apellis Pharmaceuticals?: Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial